NCT02587650 2020-01-27Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV MelanomaUniversity of California, San FranciscoPhase 2 Terminated1 enrolled 7 charts
NCT02465528 2019-12-27Ceritinib Rare Indications Study in ALK+ TumorsNovartisPhase 2 Terminated22 enrolled 16 charts